Table 3 The selected MRI features to predict the cholangiocyte phenotype HCC

AFP (> 100 ng/mL vs. ≤ 100 ng/mL)

 − 0.476

0.043

0.621 (0.392–0.985)

-

-

-

CA199 (> 30 U/mL vs. ≤ 30 U/mL)

 − 0.175

0.531

0.839 (0.485–1.452)

-

-

-

Size (> 3.0 cm vs. ≤ 3.0 cm)

0.181

0.419

1.198 (0.773–1.856)

-

-

-

Tumor margin

1.030

 < 0.001

2.801 (1.628–4.818)

0.443

0.155

1.557 (0.845–2.871)

Tumor growth subtype (single nodular vs. other)

0.504

0.027

1.655 (1.060–2.586)

-

-

-

Marked diffusion restriction

0.343

0.238

1.408 (0.798–2.487)

-

-

-

Marked T2 hyperintense

0.793

0.142

2.209 (0.768–6.357)

-

-

-

Fat in mass more than liver

 − 0.236

0.309

0.789 (0.500–1.245)

-

-

-

Fat sparing in solid mass

0.246

0.622

1.279 (0.481–3.401)

-

-

-

Non-rim APHE

 − 1.561

 < 0.001

0.210 (0.114–0.388)

-

-

-

Rim APHE

1.839

 < 0.001

6.290 (3.285–12.046)

1.769

 < 0.001

5.866 (2.868–11.998)

Internal artery

 − 0.089

0.716

0.915 (0.566–1.478)

-

-

-

Corona enhancement

0.296

0.185

1.344 (0.868–2.082)

-

-

-

Nonperipheral washout

 − 0.699

0.007

0.497 (0.298–0.828)

-0.573

0.058

0.564 (0.311–1.021)

Peripheral washout

2.485

0.020

12.00 (1.483–97.084)

-

-

-

Delayed central enhancement

1.621

0.001

5.056 (1.963–13.021)

-

-

-

PVP peritumoral hypo-enhancement

0.001

0.997

1.001 (0.594–1.687)

-

-

-

Complete capsule

 − 1.079

 < 0.001

0.340 (0.190–0.608)

-

-

-

Blood products in mass

0.067

0.790

1.070 (0.652–1.755)

-

-

-

Nodule in nodule

1.170

 < 0.001

3.221 (2.043–5.077)

1.263

 < 0.001

3.537 (2.118–5.906)

Mosaic architecture

0.538

0.026

1.712 (1.068–2.744)

-

-

-

Infiltrative appearance

0.135

0.682

1.144 (0.600–2.182)

-

-

-

Necrosis or severe ischemia

 − 0.173

0.480

0.841 (0.520–1.360)

-

-

-

Tumor in vein

 − 0.144

0.757

0.866 (0.349–2.150)

-

-

-

LI-RADS M^#

0.703

0.046

2.019 (1.012–4.029)

-

-

-